{"context":{"query":">>mondo>>clinical_trials","source_dataset":"mondo","target_dataset":"clinical_trials"},"stats":{"queried":1,"total":100,"mapped":1},"pagination":{"has_next":true,"next_token":"-1[]MONDO:0005301,73,MONDO:0005301,120,1]["},"schema":"id|brief_title|overall_status|phase|study_type","mappings":[{"input":"MONDO:0005301","source":"MONDO:0005301|multiple sclerosis","targets":["NCT00037102|Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00037115|Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT00146068|EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00151294|The Efficacy and Safety of Escitalopram for Depression in Multiple Sclerosis|TERMINATED|PHASE4|INTERVENTIONAL","NCT00176592|Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI|COMPLETED|PHASE4|INTERVENTIONAL","NCT00179478|Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00220922|A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00239993|A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®|COMPLETED|PHASE4|INTERVENTIONAL","NCT00240006|A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone|COMPLETED|PHASE4|INTERVENTIONAL","NCT00240032|A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.|COMPLETED|PHASE4|INTERVENTIONAL","NCT00246324|Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00267319|FOCUS Fatigue Outcome in Copaxone USers|COMPLETED|PHASE4|INTERVENTIONAL","NCT00381264|Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00414453|Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis|TERMINATED|PHASE4|INTERVENTIONAL","NCT00423527|Levetiracetam in Central Pain in Multiple Sclerosis(MS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT00480181|Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00492765|Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00493077|Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy|COMPLETED|PHASE4|INTERVENTIONAL","NCT00536120|The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00629642|Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT00638027|Memantine for Spasticity in MS Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT00744679|A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State|COMPLETED|PHASE4|INTERVENTIONAL","NCT00752778|Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri|TERMINATED|PHASE4|INTERVENTIONAL","NCT00753792|Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse|COMPLETED|PHASE4|INTERVENTIONAL","NCT00854750|Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis|TERMINATED|PHASE4|INTERVENTIONAL","NCT00881205|Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment|TERMINATED|PHASE4|INTERVENTIONAL","NCT00910598|Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT00913666|Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers|COMPLETED|PHASE4|INTERVENTIONAL","NCT00915460|Open-Label Safety Extension Study of Avonex|COMPLETED|PHASE4|INTERVENTIONAL","NCT00942214|Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment|COMPLETED|PHASE4|INTERVENTIONAL","NCT00988988|The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT01005095|The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients|TERMINATED|PHASE4|INTERVENTIONAL","NCT01034579|The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial|COMPLETED|PHASE4|INTERVENTIONAL","NCT01085318|Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial|COMPLETED|PHASE4|INTERVENTIONAL","NCT01236534|Lubiprostone in Patients With Multiple Sclerosis Associated Constipation|COMPLETED|PHASE4|INTERVENTIONAL","NCT01333501|Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms|COMPLETED|PHASE4|INTERVENTIONAL","NCT01339676|Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)|UNKNOWN|PHASE4|INTERVENTIONAL","NCT01356940|A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01395316|Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01411514|Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis|TERMINATED|PHASE4|INTERVENTIONAL","NCT01454791|Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate|COMPLETED|PHASE4|INTERVENTIONAL","NCT01480076|Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01556685|MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia|COMPLETED|PHASE4|INTERVENTIONAL","NCT01578330|A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720|COMPLETED|PHASE4|INTERVENTIONAL","NCT01585298|STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)|COMPLETED|PHASE4|INTERVENTIONAL","NCT01621269|ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT01656148|FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra|COMPLETED|PHASE4|INTERVENTIONAL","NCT01767493|Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT01791244|A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device|COMPLETED|PHASE4|INTERVENTIONAL","NCT01795872|Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT01834586|Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications|COMPLETED|PHASE4|INTERVENTIONAL","NCT01838174|A Trial of Neuroprotection With ACTH in Acute Optic Neuritis|TERMINATED|PHASE4|INTERVENTIONAL","NCT01888354|Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations|COMPLETED|PHASE4|INTERVENTIONAL","NCT01895335|Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT01930708|A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes|COMPLETED|PHASE4|INTERVENTIONAL","NCT01930799|Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns|COMPLETED|PHASE4|INTERVENTIONAL","NCT01964547|A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT01968902|Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT01970410|MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV|COMPLETED|PHASE4|INTERVENTIONAL","NCT01986998|Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse|COMPLETED|PHASE4|INTERVENTIONAL","NCT02040116|Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases|COMPLETED|PHASE4|INTERVENTIONAL","NCT02048072|Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS|COMPLETED|PHASE4|INTERVENTIONAL","NCT02086188|Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT02090348|Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT02117050|RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate|TERMINATED|PHASE4|INTERVENTIONAL","NCT02143167|Resistance Training and Amino Pyridine in Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT02146534|Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients|COMPLETED|PHASE4|INTERVENTIONAL","NCT02232061|Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks|COMPLETED|PHASE4|INTERVENTIONAL","NCT02234869|Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT02241785|Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies|TERMINATED|PHASE4|INTERVENTIONAL","NCT02254304|Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™|COMPLETED|PHASE4|INTERVENTIONAL","NCT02259361|Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02343159|Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.|TERMINATED|PHASE4|INTERVENTIONAL","NCT02410278|Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera|COMPLETED|PHASE4|INTERVENTIONAL","NCT02446886|Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS|TERMINATED|PHASE4|INTERVENTIONAL","NCT02499900|Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®|COMPLETED|PHASE4|INTERVENTIONAL","NCT02665221|Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY|TERMINATED|PHASE4|INTERVENTIONAL","NCT02670161|Quality Improvement and Practice Based Research in Neurology Using the EMR|ENROLLING_BY_INVITATION|PHASE4|INTERVENTIONAL","NCT02675413|Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS|WITHDRAWN|PHASE4|INTERVENTIONAL","NCT02683863|Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers|COMPLETED|PHASE4|INTERVENTIONAL","NCT02739542|Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT02769689|Methylprednisolone During the Switch Between Natalizumab and Fingolimod|UNKNOWN|PHASE4|INTERVENTIONAL","NCT02775110|Natalizumab Temporary Discontinuation Study|COMPLETED|PHASE4|INTERVENTIONAL","NCT02849782|Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.|COMPLETED|PHASE4|INTERVENTIONAL","NCT02904876|Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis|TERMINATED|PHASE4|INTERVENTIONAL","NCT03021317|Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses|TERMINATED|PHASE4|INTERVENTIONAL","NCT03046251|Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03073603|Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT03092544|Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03110315|A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia|COMPLETED|PHASE4|INTERVENTIONAL","NCT03135249|Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03257358|A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod|COMPLETED|PHASE4|INTERVENTIONAL","NCT03269175|BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies|COMPLETED|PHASE4|INTERVENTIONAL","NCT03364036|Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)|COMPLETED|PHASE4|INTERVENTIONAL","NCT03369665|Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)|COMPLETED|PHASE4|INTERVENTIONAL","NCT03424733|Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects|UNKNOWN|PHASE4|INTERVENTIONAL","NCT03516526|Towards Personalized Dosing of Natalizumab in Multiple Sclerosis|COMPLETED|PHASE4|INTERVENTIONAL","NCT03589105|A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting|COMPLETED|PHASE4|INTERVENTIONAL","NCT03621761|Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue|COMPLETED|PHASE4|INTERVENTIONAL","NCT03784898|Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada|COMPLETED|PHASE4|INTERVENTIONAL"]}]}